As the FDA seeks to bring a greater focus to improving post-market evidence generation, a new report from the Reagan-Udall Foundation offers some potential solutions to the system it says is too costly and complicated.
The notorious contamination of infant formula over the winter of 2021-22 was a scandal not only for Abbot Nutrition, the product’s manufacturer, but for the federal Food and Drug Administration (FDA), which dawdled for five months before taking action.
On November 13, 2023, the Alliance for a Stronger FDA hosted a webinar with James "Jim" Jones, the recently appointed Deputy Commissioner for Human Foods at the U.S. Food and Drug Administration (FDA), during which he discussed his priorities, plans, and approach to change at the agency.
The nonprofit Reagan-Udall Foundation that advises the FDA is recommending the agency lead an inter-agency and industry task force to streamline and strengthen post-approval studies of drugs and devices.
An Alliance for a Stronger FDA webinar on Monday, Nov. 13, will feature Jim Jones, FDA Deputy Commissioner for Human Foods. Alison Bodor of the American Frozen Foods Institute, and Thomas Gremillion of the Consumer Federation of America, will moderate.
When bacteria develop resistance to front-line antibiotics, health care professionals lose their ability to treat deadly infections, leading to more than 35,000 deaths annually in the U.S. and more than 1.2 million worldwide.
The U.S. Food and Drug Administration’s Center for Tobacco Products (CTP) has made significant progress in addressing the recommendations made by an expert panel facilitated by the Reagan-Udall Foundation, CTP Director Brian King said in a recent update.
A broad and odd collection of groups today announced the launch of the FDA Foods Coalition, meant to support and lobby the food safety agency as it develops its planned Human Foods Program.
FDA Commissioner Robert Califf, MD, recently said the need to address misinformation is “probably the most difficult issue in my career.” Delivering accurate, understandable, and timely health information to the public, as well as to experts trusted by the public, is “an astounding challenge,” he said at a virtual public hearing in which the
Expert advisers will consider today how two companies assessed potential risks with their proposed first-ever gene-editing treatment for sickle cell disease, a rare condition that disproportionately affects people of color.
